(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number
WO 03/080021 A2

(51) International Patent Classification[7]: A61K 9/00

(21) International Application Number: PCT/GB03/01183

(22) International Filing Date: 19 March 2003 (19.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0206448.3	19 March 2002 (19.03.2002)	GB
0225040.5	28 October 2002 (28.10.2002)	GB
0225041.3	28 October 2002 (28.10.2002)	GB
0225042.1	28 October 2002 (28.10.2002)	GB

(71) Applicants *(for all designated States except US)*: **IONIX PHARMACEUTICALS LIMITED** [GB/GB]; 185 Cambridge Science Park, Milton Road, Cambridge CB4 0GA (GB). **WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED** [GB/GB]; Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG7 2TN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BIRCH, Phillip, John** [GB/GB]; 185 Cambridge Science Park, Milton Road, Cambridge CB4 0GA (GB). **HAYES, Ann, Gail** [GB/GB]; 185 Cambridge Science Park, Milton Road, Cambridge CB4 0GA (GB). **WATTS, Peter, James** [GB/GB]; Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG7 2TN (GB). **CASTILE, Jonathan, David** [GB/GB]; Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG7 2TN (GB).

(74) Agent: **WOODS, Geoffrey Corlett**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

[Continued on next page]

(54) Title: FORMULATION



(57) Abstract: Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C_{ther}, of 0.2 ng/ml or greater which is maintained for a duration T_{maint} of at least 2 hours.

WO 03/080021 A2

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.